Page not available
If you are a health care professional affiliated with an employer, institution or
committee, or practicing in a state, that restricts what items you may receive from
manufacturers, we ask that you not accept or download any restricted items from
this site. If you are a health care provider practicing in Vermont, we are required
by state law to deny you permission to download any items or review any journal
articles made available on this site.
The page you are trying to access is no longer available. However, you may find
these other patient resources helpful.
Mom's Guide to Nebulizing
Patients can get tips from other moms on how to make nebulizing easier for their
child, how to care for their nebulizer, and how to familiarize caregivers with nebulizing.
Asthma Trigger Tracker
Provide your patients with a list of common triggers, along with tips on how to
IMPORTANT SAFETY INFORMATION ABOUT PULMICORT
PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of
Particular care is needed for patients who are transferred from systemically active
corticosteroids to PULMICORT RESPULES, because deaths due to adrenal insufficiency
have occurred in asthmatic patients during and after transfer from systemic corticosteroids
to less systemically available inhaled corticosteroids.
It is possible that systemic corticosteroid effects such as hypercorticism, reduced
bone mineral density, and adrenal suppression may appear in a small number of patients,
particularly at higher doses.
Patients taking immunosuppressant doses of corticosteroids should avoid exposure
to infections such as chicken pox and measles.
Inhaled corticosteroids may cause a reduction in growth velocity. The long-term
effect on final adult height is unknown.
Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.
As with other inhaled medications, paradoxical bronchospasm may occur with
In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic
conditions and clinical features consistent with Churg-Strauss Syndrome.
Adverse reactions that occurred at a rate of ≥ 3% are: respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, and rash.
PULMICORT RESPULES (budesonide inhalation suspension) is indicated for the maintenance
treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.
for full Prescribing Information for PULMICORT RESPULES.
You are encouraged to report negative side effects of prescription
drugs to the FDA.
Visit www.FDA.gov/medwatch or call